International Journal of Pharmacology and Clinical Sciences, 2015, 4, 1, 7-11.
Published: March 2015
Type: Research Article
Authors: Athira B, Manju CS, Jyothi E
Author(s) affiliations:
Athira B1*, Manju CS2, Jyothi E3
1M.Pharm student,
2Assistant Professor, College of pharmaceutical sciences, Government Medical College, Kozhikode, Kerala, India.
3Assistant Professor, Institute of Chest Disease, Government Medical College, Kozhikode, Kerala, India.
Abstract
Background: Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis, is the second leading infectious cause of death in the world. The objective was to study the demographic details of the tuberculosis patients experiencing adverse drug reactions (ADRs) and to identify the frequency of adverse drug reactions. Materials and Methods: It was a prospective observational study conducted in the pulmonology department of the Institute of Chest Disease, Govt. Medical College, Kozhikode, Kerala, India. All the TB patients admitted at the directly observed treatment, short course (DOTS) Center at Medical College Hospital were enrolled and were monitored for ADRs. The causality and severity of the reactions were determined using the Naranjo algorithm and Hartwig questionnaire, respectively. Results: A total of 511 tuberculosis patients who were on DOTS therapy were enrolled for the study. Out of 511 patients, 93 patients (18.20%) developed adverse drug reactions. The higher numbers of ADRs were observed in males (68.81%) and the remaining (31.18%) was observed in females. Diabetes mellitus (41.02%) was the most common comorbidity. Most of the ADR occurred in the intensive phase (85.71%) of treatment. It was observed that pulmonary TB (55.18%) was more common than extra-pulmonary TB. The majority of adverse drug reactions were gastrointestinal (GI) problems (38.09%). The most serious ADR was hepatitis. Isoniazid was the major drug which caused 34.40% of adverse drug reactions.
Conclusion: About 17.02% of people developed different types of ADRs during the study period. As a pharmacist, we have the liability to support the patients during the period of antitubercular treatment. These ADRs may steer the patient to make a judgment for stopping the medications and finally the occurrence of drug resistance and an amplified healthcare cost. If a proper educational system is implemented, most of the patients may report their ADR and thereby we can improve the patient adherence and therapeutic outcome.
Keywords: Adverse drug reactions, Ethambutol, Isoniazid, Pyrazinamide, Rifampicin, Tuberculosis